

APR 21 2006

Atty. Docket No.18528.634/ 0101-UTL-0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Patent Application of:
B. Gedulin, et al.

Serial No.: 10/671,304

Filed: September 24, 2003

Title: TREATMENT OF PANCREATITIS
WITH AMYLIN

Confirmation No.: 8486


Group Art Unit: 1655

Examiner: WINSTON, Randall O.

Atty Docket 18528.643/ 0101-UTL-0

FACSIMILE TRANSMITTAL COVER SHEET**Certificate of Transmission Under 37 C.F.R. 1.8**

I hereby certify that the following listed correspondence in the above-referenced application is being transmitted by facsimile to the Commissioner for Patents, Alexandria, VA to telephone number (571) 273-8300 on this 21st day of April, 2006.


Amanda J. Halverson**Document(s)****No. of Pages****1. Response to Restriction Requirement****2****Total number of pages transmitted (including this page):****3**

***NOTE: Each paper must have its own certificate of transmission,
or this certificate must identify each paper submitted***

APR 21 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
B. Gedulin, et al.

Serial No.: 10/671,304

Filed: September 24, 2003

Title: TREATMENT OF PANCREATITIS
WITH AMYLIN

Confirmation No.: 8486

Group Art Unit: 1655

Examiner: WINSTON, Randall O.

Atty Docket 18528.643/ 0101-UTL-0

Response to Restriction Requirement

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the Office Action mailed March 23, 2006, which sets forth a restriction requirement for pending claims 1-20 in the above-identified application. A response to this action is due April 23, 2006. Accordingly, this response is timely filed.


At page 2 of the Office Action, the Examiner states that Applicants are required under 35 U.S.C. §121 to elect a single disclosed species from the list of a) amylin, b) amylin analog, and c) amylin agonist for prosecution on the merits. Applicants hereby elect species c) amylin analog. Applicants request that, upon allowance of a generic claim, the remainder of the species be included as permitted under 37 C.F.R. §1.141.

Applicants request examination of the elected subject matter on the merits.

CERTIFICATE FACSIMILE TRANSMISSION UNDER 37 C.F.R. 1.8

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the USPTO at facsimile number (571) 273-8300, to the Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

April 21, 2006
Date of Deposit


Signature of Person Mailing Paper

Amanda J. Halverson
Name of Person Mailing Paper

USSN 10/671,304
Atty Docket 18528.643/ 0101-UTL-0
Page 2


Applicants believe that all issues raised in the Office Action have been properly addressed in this response. If the Examiner feels that a telephone interview would serve to facilitate resolution of any outstanding issues, the examiner is encouraged to contact Applicants' representative at the telephone number below.

No additional fees are believed due for this submission. However, if a fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication, to Applicant's Deposit Account No. 010535 referencing Docket No. 0101-UTL-0. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Date: 21 April 2006

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.



Karen R. Zachow, Ph.D.
Reg. No. 46,332

Amylin Pharmaceuticals, Inc.
9360 Towne Centre Drive
San Diego, California 92121
Phone (858) 552-2200
Facsimile (858) 552-1936